Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Predictability of the Initial Response to a Low Dose of Risperidone on the Middle Term Efficiency in Anxious Subjects

NCT03227562 is registered in ClinicalTrials.gov with Marion Trousselard as lead sponsor.

NCT NCT03227562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03227562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Predictability of the Initial Response to a Low Dose of Risperidone on the Middle Term Efficiency in Anxious Subjects
Lead sponsor
Marion Trousselard
Phase
Phase 3
Overall status
Terminated
Start date
September 1, 2017
Completion date
December 1, 2021
Enrollment
120 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anxiety state